NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.10 -0.04 (-0.65 %)
(As of 03/20/2019 05:20 AM ET)
Previous Close$6.14
Today's Range$6.10 - $6.11
52-Week Range$5.52 - $25.55
Volume2,200 shs
Average Volume12,740 shs
Market Capitalization$80.07 million
P/E Ratio-3.02
Dividend YieldN/A
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VRNA



Sales & Book Value

Annual SalesN/A
Book Value$6.40 per share


Net Income$-26,560,000.00


Market Cap$80.07 million
Next Earnings Date5/14/2019 (Estimated)
OptionableNot Optionable

VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for VERONA PHARMA P/S.

What price target have analysts set for VRNA?

3 analysts have issued 1 year price objectives for VERONA PHARMA P/S's stock. Their forecasts range from $26.00 to $56.00. On average, they expect VERONA PHARMA P/S's stock price to reach $39.6667 in the next twelve months. This suggests a possible upside of 550.3% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.

What is the consensus analysts' recommendation for VERONA PHARMA P/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.

What are Wall Street analysts saying about VERONA PHARMA P/S stock?

Here are some recent quotes from research analysts about VERONA PHARMA P/S stock:
  • 1. Wedbush analysts commented, "FDA approved Cabometyx (cabozantinib) for patients with advanced HCC post sorafenib treatment. The approval is an important milestone supporting cabozantinib growth beyond RCC and MTC into the large HCC opportunity. The approval is based on Ph3 Celestial data demonstrating statistically significant improvements in OS of cabozantinib (10.2 months) vs placebo (8.0 months). Median PFS was more than doubled with cabozantinib (5.2 months) vs placebo (1.9 months). Safety was acceptable with 16% discontinuations on drug. We expect an immediate launch since sales force was prepared and a small impact on SG&A. We expect launch ramp in HCC slightly below RCC despite the unmet need, since HCC treatment regimen is less well established and involves outsized use of radiation therapy. HCC approval should support continued cabozantinib growth." (1/14/2019)
  • 2. According to Zacks Investment Research, "Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. " (11/10/2018)

Has VERONA PHARMA P/S been receiving favorable news coverage?

Media stories about VRNA stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VERONA PHARMA P/S earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VERONA PHARMA P/S investors own include Sorrento Therapeutics (SRNE), Zymeworks (ZYME), Viking Therapeutics (VKTX), ZEALAND PHARMA/S (ZEAL), Teladoc Health (TDOC), Cara Therapeutics (CARA), VBI Vaccines (VBIV), MOTIF BIO PLC/S (MTFB), ServiceNow (NOW) and Zoetis (ZTS).

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 63)
  • Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
  • Ms. Claire Louise Poll B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 51)
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 56)
  • Mr. Richard Hennings, Commercial Director (Age 48)


(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Aisling Capital Management LP (3.38%), Foresite Capital Management III LLC (1.57%) and Wedbush Securities Inc. (0.11%).

Which major investors are selling VERONA PHARMA P/S stock?

VRNA stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC.

Which major investors are buying VERONA PHARMA P/S stock?

VRNA stock was purchased by a variety of institutional investors in the last quarter, including Aisling Capital Management LP and Wedbush Securities Inc..

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $6.10.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $80.07 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]

MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by Staff

Featured Article: Is the QQQ ETF safe?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel